
Sarah Forward
Articles
-
Nov 1, 2024 |
jitc.bmj.com | Trevor Brown |Marissa Fahlberg |Sarah Forward |Emane Rose Assita
AbstractBackground Cell therapy has been successful for treating some hematological malignancies, largely through autologous chimeric antigen receptor (CAR) T-cell therapies. However, the complexity of CAR T-cell therapies makes them costly and time-consuming to develop.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →